Cantargia AB (CANTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cantargia AB (CANTA) has a cash flow conversion efficiency ratio of 0.943x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr280.72 Million ≈ $30.21 Million USD) by net assets (Skr297.57 Million ≈ $32.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CANTA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Cantargia AB - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Cantargia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cantargia AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cantargia AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing North Star Company Limited
F:BJ3
|
0.078x |
|
Marchex Inc
NASDAQ:MCHX
|
0.004x |
|
Suzhou QingYue Optoelectronics Technology Co. Ltd. A
SHG:688496
|
N/A |
|
Suprema ID Inc
KQ:317770
|
0.014x |
|
PP Properti Tbk PT
JK:PPRO
|
0.001x |
|
JLS Co.Ltd
KQ:040420
|
0.043x |
|
SERESCO (ACC.P.DESD.)-16
F:XV7
|
N/A |
|
Gentian Diagnostics AS
OL:GENT
|
0.208x |
Annual Cash Flow Conversion Efficiency for Cantargia AB (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cantargia AB from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see CANTA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr116.30 Million ≈ $12.52 Million |
Skr-162.75 Million ≈ $-17.51 Million |
-1.399x | +17.63% |
| 2023-12-31 | Skr168.74 Million ≈ $18.16 Million |
Skr-286.66 Million ≈ $-30.85 Million |
-1.699x | -84.45% |
| 2022-12-31 | Skr389.68 Million ≈ $41.94 Million |
Skr-358.92 Million ≈ $-38.62 Million |
-0.921x | -41.63% |
| 2021-12-31 | Skr532.75 Million ≈ $57.33 Million |
Skr-346.44 Million ≈ $-37.28 Million |
-0.650x | -270.89% |
| 2020-12-31 | Skr891.93 Million ≈ $95.99 Million |
Skr-156.39 Million ≈ $-16.83 Million |
-0.175x | +77.58% |
| 2019-12-31 | Skr142.27 Million ≈ $15.31 Million |
Skr-111.25 Million ≈ $-11.97 Million |
-0.782x | -15.81% |
| 2018-12-31 | Skr155.04 Million ≈ $16.69 Million |
Skr-104.69 Million ≈ $-11.27 Million |
-0.675x | -304.30% |
| 2017-12-31 | Skr246.12 Million ≈ $26.49 Million |
Skr-41.10 Million ≈ $-4.42 Million |
-0.167x | +84.31% |
| 2016-12-31 | Skr37.13 Million ≈ $4.00 Million |
Skr-39.53 Million ≈ $-4.25 Million |
-1.065x | +1.35% |
| 2015-12-31 | Skr28.05 Million ≈ $3.02 Million |
Skr-30.28 Million ≈ $-3.26 Million |
-1.079x | -164.11% |
| 2014-12-31 | Skr4.10 Million ≈ $440.95K |
Skr6.90 Million ≈ $742.32K |
1.683x | +163.81% |
| 2013-12-31 | Skr3.13 Million ≈ $337.02K |
Skr-8.26 Million ≈ $-889.18K |
-2.638x | -114.81% |
| 2012-12-31 | Skr3.08 Million ≈ $331.15K |
Skr-3.78 Million ≈ $-406.73K |
-1.228x | +35.02% |
| 2011-12-31 | Skr1.54 Million ≈ $165.99K |
Skr-2.92 Million ≈ $-313.74K |
-1.890x | -- |
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more